Intravenous immunoglobulins for treatment of connective tissue diseases in dermatology

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Wiener Medizinische Wochenschrift

• Publication date

  2018-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10354-017-0595-xPMID 28864939
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Developing standardised treatment for adults with myositis and different phenotypes: an international survey of current prescribing preferences.

  2016cited by this paper
• Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases

  2016cited by this paper
• Pompholyx as a clinical manifestation suggesting increased serum IgG levels in a patient with drug‐induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms

  2016cited by this paper
• Successful treatment of systemic lupus erythematosus with subcutaneous immunoglobulin

  2016cited by this paper
• IVIG inhibits TNF-α-induced MMP9 expression and activity in monocytes by suppressing NF-κB and P38 MAPK activation.

  2015cited by this paper
• Cost-Utility Analysis of Intravenous Immunoglobulin for the Treatment of Steroid-Refractory Dermatomyositis in Thailand

  2015cited by this paper
• Efficacy of Intravenous Immunoglobulin Monotherapy in Patients with Cutaneous Lupus Erythematosus: Results of Proof-of-Concept Study

  2015cited by this paper
• Intravenous Immune Globulin in Amyopathic Dermatomyositis - Report of Two Cases and Review of the Literature

  2015cited by this paper
• Long-Term, High-Dose Intravenous Immunoglobulin Therapy in a Patient with Banker-Type Juvenile Dermatomyositis

  2014cited by this paper
• A randomised , double-blind , placebo-controlled trial : intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis

  2013cited by this paper
• Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective study

  2013cited by this paper
• Nephrotic syndrome in Kawasaki disease: a report of three cases

  2012cited by this paper
• Refractory subacute cutaneous lupus erythematosus treated with rituximab

  2012cited by this paper
• Refractory calcinosis in a patient with dermatomyositis: response to intravenous immune globulin

  2012cited by this paper
• Broadened T-cell Repertoire Diversity in ivIg-treated SLE Patients is Also Related to the Individual Status of Regulatory T-cells

  2012cited by this paper
• [Refractory subacute cutaneous lupus erythematosus treated with rituximab].

  2012cited by this paper
• Lupus eritematoso cutáneo subagudo refractario tratado con rituximab

  2012cited by this paper
• Large leg ulcers due to autoimmune diseases

  2011cited by this paper
• The Role of Intravenous Immunoglobulin Preparations in the Treatment of Systemic Sclerosis

  2011cited by this paper
• Intravenous Immunoglobulin in Lupus Panniculitis

  2010cited by this paper
• Relevant Criteria for Selecting an Intravenous Immunoglobulin Preparation for Clinical Use

  2010cited by this paper
• Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada

  2010cited by this paper
• Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases.

  2009cited by this paper
• Combined plasmapheresis and high-dose intravenous immunoglobulin treatment in systemic sclerosis for 12 months: follow-up of immunopathological and clinical effects

  2008cited by this paper
• Successful treatment of cutaneous lesions in juvenile dermatomyositis with high‐dose intravenous immunoglobulin

  2007cited by this paper
• Clinical Manifestations of Cutaneous Lupus Erythematosus

  2007cited by this paper
• Intravenous immunoglobulin: properties, mode of action and practical use in dermatology.

  2007cited by this paper
• High‐dose intravenous immunoglobulin infusion as treatment for diffuse scleroderma

  2007cited by this paper
• Intravenous Immunoglobulin: An Update on the Clinical Use and Mechanisms of Action

  2007cited by this paper
• Intravenous immunoglobulin in the treatment of resistant subacute cutaneous lupus erythematosus: a possible alternative

  2007cited by this paper
• Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature.

  2006cited by this paper
• Intravenous immunoglobulin for recalcitrant subacute cutaneous lupus erythematosus.

  2005cited by this paper
• A case of diffuse scleroderma successfully treated with high-dose intravenous immune globulin infusion.

  2005cited by this paper
• Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study.

  2004cited by this paper
• Intravenous immunoglobulin (IVIg) for therapy‐resistant cutaneous lupus erythematosus (LE)

  2004cited by this paper
• Fasciitis in mixed connective tissue disease successfully treated with high-dose intravenous immunoglobulin.

  2003cited by this paper
• Efficacy of pulsed intravenous immunoglobulin therapy in mixed connective tissue disease.

  2002cited by this paper
• Dermatomyositis: cutaneous manifestations of its variants

  2002cited by this paper
• Intravenous immunoglobulin treatment of lupus nephritis.

  2000cited by this paper
• Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis.

  1999cited by this paper
• Low‐Dose Intravenous Immunoglobulin Therapy for Intractable Dermatomyositis Skin Lesions

  1999cited by this paper
• High-dose intravenous immunoglobulin in cutaneous lupus erythematosus.

  1999cited by this paper
• Disabling morphoea of childhood—beneficial effect of intravenous immunoglobulin therapy

  1998cited by this paper
• INTRAVENOUS IMMUNOGLOBULIN THERAPY IN DERMATOLOGY. OVERVIEW AND CENTER EXPERIENCE

  1998influential reference
• Effect of high‐dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: Assessments based on controlled treatment trials in patients with neurological diseases

  1997cited by this paper
• Intravenous immunoglobulin therapy is not able to efficiently control cutaneous manifestations in patients with lupus erythematosus

  1997cited by this paper
• High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments.

  1994cited by this paper
• Aseptic Meningitis Associated with High-Dose Intravenous Immunoglobulin Therapy: Frequency and Risk Factors

  1994cited by this paper
• High‐dose intravenous immunoglobulin and serum viscosity

  1994cited by this paper
• A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis.

  1993cited by this paper
• Efficacy of intravenous immunoglobulins in sclerodermatomyositis

  1990cited by this paper
• Use of high-dose intravenous immunoglobulin in systemic lupus erythematosus: report of three cases.

  1989cited by this paper
• Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA.

  1986cited by this paper
• High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood.

  1981cited by this paper
• High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura.

  1981cited by this paper
• Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA).

  1972cited by this paper
• Agammaglobulinemia.

  1952cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet. Polymyositis and Dermatomyositis

  year unknowncited by this paper

• High-dose immunoglobulin therapy for steroid-resistant myositis in juvenile localized scleroderma.

  2022cites this paper
• Autoimmune connective tissue diseases in the COVID-19 pandemic

  2020cites this paper
• Intravenous immunoglobulin treatment: Where do dermatologists stand?

  2019cites this paper
• Bulgarian rheumatology: science and practice in a cost-constrained environment

  2018cites this paper
• Cutaneous Manifestations of Dermatomyositis: a Comprehensive Review

  2017cites this paper